William Blair initiated coverage of Aardvark Therapeutics with a rating of Outperform

Raymond James initiated coverage of Aardvark Therapeutics with a rating of Strong Buy and set a new price target of $47.00

BTIG Research initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $26.00

Stifel initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $24.00

H.C. Wainwright initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $40.00

Morgan Stanley initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $29.00

BofA Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $22.00

RBC Capital Mkts initiated coverage of Aardvark Therapeutics with a rating of Outperform and set a new price target of $21.00

Cantor Fitzgerald initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $50.00

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivo

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December: Piper Sandler 37th Annual Healthcare Conference in New YorkPresentation: Wednesday, December 3 at 8:00 a.m. ETEvercore ISI 8th Annual Healthcare Conference in MiamiPresentation: Thursday, December 4 at 11:15 a.m. ET Live webcasts of each presentation will be accessible on the company's website, www.aardvarktherapeutics.com, under the i

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced glucose control, along with preservation of lean body mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape Oral ARD-201 shows potential for weight management after GLP-1RA discontinuation, supported by new promising preclinical results and ARD-101 clinical data $126.4 million in cash, cash equivalents, and

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 4,881 shares of common stock. The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee's employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape  Preclinical and clinical data demonstrates the potential of ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after the discontinuation of GLP-1RA Aardvark to host investor webinar on November 5th, 2025 to review ARD-101 and ARD-201 programs, as well as ObesityWeek presentations SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on develop

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 23,602 shares of common stock, (ii) on October 28, 2025, three new employees were granted inducement awards consisting of stock options to purchase an aggregate of 49,849 shares of common stock and (iii) on November 3, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 14,766

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during November: Stifel 2025 Healthcare Conference in New YorkPresentation: Tuesday, November 11 at 4:40 p.m. ET TD Cowen Treatment Advancements in Obesity & Related Disorders Summit (virtual) Presentation: Monday, November 24 at 3:00 p.m. ET Live webcasts of each presentation will be accessible on the company's website, www.aardvarktherapeutics.com, un

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present poster presentations at ObesityWeek 2025, which is being held on November 4-7, 2025 in Atlanta, Georgia. ObesityWeek Presentation Details: Title: TAS2R Pan-Agonist ARD-101 Attenuates Weight Gain in Mice and Reduces Hunger in Adults with ObesityDate and Time: Tuesday, November 4, 2025 at 7:30 p.m. - 8:30 p.m. ETPresenter: Timothy Kieffer, Ph.D., Chief Scientific Officer of Aardvark

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announces alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment to the company's Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS). The protocol amendment changes the minimum age of eligibility to participate in the trial from 13 to 10 years old. "Expansion of the Phase 3 HERO trial to include children 10 years of age and older w

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 at 9:00 a.m. Eastern time. A live webcast presentation will be accessible on the company's website, www.aardvarktherapeutics.com, under the investors section, and an archived recording will be available on the website for approximately one month following each presentation. About Aardvark Therapeutics, Inc.Aardv

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

S-8 - Aardvark Therapeutics, Inc. (0001774857) (Filer)

10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. "It's an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS," said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. "The United in